ABRE Study - 36-month clinical outcomes

The ABRE Study shows clinically meaningful impact on quality of life through 36 months — even in the most complex patients.


Review cinical outcomes

47.5%

categorized as PTS patients

35.8%

of PTS patients presented with complete vein occlusion

112.4 mm

average lesion length

44.0%

patients with stents extending below inguinal ligament†
Graph - 16.6% aDVT patients
Graph - 47.5% PTS patients
Graph - 36% NVL patients

† Site and core lab data were used.
Source: Abre stent IFU.


See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

medtronic.eu/abre


© 2023 Medtronic. All rights reserved. UC202403554-cirse-2023-post-congress-eblast-for-abre-en-emea-10231629



Medtronic